<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04189263</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2018-21-AMERSI-BREADS</org_study_id>
    <nct_id>NCT04189263</nct_id>
  </id_info>
  <brief_title>BREADS: Breast Adjuvant Diet Study</brief_title>
  <official_title>IIT2018-21-Amersi-BREADS BREADS: Breast Adjuvant Diet Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Farin Amersi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial of a 6-month extreme carbohydrate restricted diet (20&#xD;
      grams total carbs/day) via phone counseling with dietitian plus aromatase inhibitor therapy&#xD;
      vs. 6-month control with aromatase inhibitor therapy alone. Visits will occur at screening, 3&#xD;
      months, and 6 months. Anthropomorphic measurements (such as heart rate, weight, and body&#xD;
      measurement) and questionnaires will be taken at all three visits. After screening, patients&#xD;
      will be randomized to receive the carbohydrate restricted diet coaching immediately (Arm A)&#xD;
      or to a control group (Arm B). Patients randomized to Arm A will receive weekly calls for the&#xD;
      first 3 months of the intervention, then biweekly calls for the last 3 months of the&#xD;
      intervention from the study dietitian. Total duration of the study is expected to be 3 years,&#xD;
      though each patient's participation will be approximately 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2020</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in weight</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in change in weight between pre- and post- intervention between carbohydrate restricted and control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in serum estradiol</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in changes in serum estradiol between pre- and post-intervention between low-carbohydrate group and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting glucose</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in changes in fasting glucose between pre- and post-intervention between low-carbohydrate group and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in insulin</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in changes in insulin between pre- and post-intervention between low-carbohydrate group and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HbA1c</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in changes in HbA1c between pre- and post-intervention between low-carbohydrate group and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in triglycerides</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in changes in triglycerides between pre- and post-intervention between low-carbohydrate group and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LDL</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in changes in LDL between pre- and post-intervention between low-carbohydrate group and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HDL</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in changes in HDL between pre- and post-intervention between low-carbohydrate group and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cholesterol</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in changes in cholesterol between pre- and post-intervention between low-carbohydrate group and control group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Dietary intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carbohydrate restricted dietary intervention (&lt;20 g carbohydrates/day) + standard of care aromatase inhibitors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No dietary intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care aromatase inhibitors</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Carbohydrate restricted dietary intervention</intervention_name>
    <description>Carbohydrate restricted dietary intervention (&lt;20 g carbohydrates/day)</description>
    <arm_group_label>Dietary intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard of care aromatase inhibitors</intervention_name>
    <description>standard of care aromatase inhibitors</description>
    <arm_group_label>Dietary intervention</arm_group_label>
    <arm_group_label>No dietary intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
          -  4.1.2 Planning to start adjuvant hormonal therapy using an aromatase inhibitor or has&#xD;
             started adjuvant hormonal therapy using an aromatase inhibitor within 14 days of&#xD;
             randomization.&#xD;
&#xD;
          -  Able to read, write, and understand English&#xD;
&#xD;
          -  BMI ≥ 24 kg/m2&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  If Her-2 positive, completed Herceptin therapy prior to enrollment&#xD;
&#xD;
          -  ER and/or PR positive (defined as having ≥ 1% staining for ER and/or PR on IHC)&#xD;
&#xD;
          -  Post-menopausal&#xD;
&#xD;
               -  The absence of menstrual cycles in women who have not undergone hysterectomy for&#xD;
                  at least 12 months preceding cancer diagnosis OR&#xD;
&#xD;
               -  History of a bilateral oophorectomy OR&#xD;
&#xD;
               -  History of a hysterectomy and age &gt;55 OR&#xD;
&#xD;
               -  No menses for &lt;1 year with FSh and estradiol levels in postmenopausal range&#xD;
                  according to institutional standards&#xD;
&#xD;
          -  ECOG Performance Status 0 or 1&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Written informed consent obtained from subject and ability for subject to comply with&#xD;
             requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of hormonal therapy other than aromatase inhibitors&#xD;
&#xD;
          -  History of other malignancy within the past 5 years, except for malignancies with a &gt;&#xD;
             95% likelihood of cure (e.g. thyroid cancer, non-melanoma skin cancer)&#xD;
&#xD;
          -  Already consuming a severe carbohydrate restricted (&lt;20 g carbohydrates per day) diet&#xD;
             or vegetarian diet&#xD;
&#xD;
          -  Plans to start chemotherapy or HER2 targeted therapy&#xD;
&#xD;
          -  Medical comorbidities that in the opinion of the investigator limits the patient's&#xD;
             ability to complete the study&#xD;
&#xD;
          -  Symptomatic metastases (Metastases allowed if asymptomatic)&#xD;
&#xD;
          -  Current use of appetite suppressant medications&#xD;
&#xD;
          -  Current use of any weight loss medications including herbal weight loss supplements or&#xD;
             if patients are enrolled in a diet/weight loss program&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farin Amersi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris Waring</last_name>
    <phone>424-315-2215</phone>
    <email>Christopher.Waring@cshs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Waring</last_name>
      <phone>424-315-2215</phone>
      <email>Christopher.Waring@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Amersi Farin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Farin Amersi</investigator_full_name>
    <investigator_title>Associate Professor, Surgery</investigator_title>
  </responsible_party>
  <keyword>aromatase inhibitor</keyword>
  <keyword>carbohydrate restricted diet</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

